1 / 23

Diabetes research update: GGC MCN meeting 5 th February 2019

Diabetes research update: GGC MCN meeting 5 th February 2019. John R Petrie Professor of Diabetic Medicine University of Glasgow, UK. Disclosures. Advisory and Consultancy Work: Novo Nordisk, Sanofi-Aventis, Biocon, Astra Zeneca, Servier Clinical trials committees:

aiko
Télécharger la présentation

Diabetes research update: GGC MCN meeting 5 th February 2019

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes research update:GGC MCN meeting 5th February 2019 John R Petrie Professor of Diabetic Medicine University of Glasgow, UK

  2. Disclosures • Advisory and Consultancy Work: • Novo Nordisk, Sanofi-Aventis, Biocon, Astra Zeneca, Servier • Clinical trials committees: • ACI Clinical (Boehringer), Janssen, NovoNordisk, Quintiles (Genentech, Roche), Sanofi-Aventis • Recipient of donation of services to support Investigator-led research: • Merck (Germany), Itamar Medical (Israel), Astra Zeneca • Investigator-led research funding: • Janssen (RISC study) • Travel and accommodation support: • Novo Nordisk, Lilly • No stock in any pharmaceutical or technology company

  3. Multicentre academic 3-year RCT of metformin in type 1 diabetes 23 centres international centres Scotland Glasgow Dundee Edinburgh Aberdeen Ayr (Steno) Denmark Canada London, Ontario Ottawa, Ontario England Newcastle Durham Manchester Hull Aintree London Plymouth Exeter Gloucester Bristol Netherlands (Maastricht) Australia Sydney Melbourne Chief Investigator: John Petrie (Glasgow) Deputy: Helen Colhoun (Edinburgh)

  4. Via clinical trials, epidemiology, translational studies and collaboration to: (i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease (ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease (iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation (iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

  5. Via clinical trials, epidemiology, translational studies and collaboration to: (i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease (ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease (iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation (iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

  6. Via clinical trials, epidemiology, translational studies and collaboration to: (i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease (ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease (iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation (iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

  7. Scottish Diabetes Research Network 2005 (SDRN)

  8. NHS Research Scotland Diabetes 2019 (NRSD or NRS Diabetes) SDRN EPIDEMIOLOGY Chair: Dr R Lindsay www.nhsresearchscotland.org.uk/research-areas/diabetes

  9. Heart failure in diabetes (3.25 million) Men Women 50 40 30 Rate per 1000 person years 20 10 0 20 20 80 80 60 60 40 40 Figure 1: Age, sex and deprivation adjusted incidence of heart failure hospitalisation (95% CIs) by diabetes type, age and sex

  10. Myocardial infarction MEN WOMEN Diabetologia, 17th Jan 2019

  11. Via clinical trials, epidemiology, translational studies and collaboration to: (i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease (ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease (iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation (iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

  12. Gill JMR, Petrie JR, Sattar N, Gray S. Mechanisms of insulin resistance in South Asians: role of muscle metabolism and microvascular perfusion. • Medical Research Council. £654,057 (2019-2022)

  13. Via clinical trials, epidemiology, translational studies and collaboration to: (i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease (ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease (iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation (iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

  14. Triple therapy in type 1 diabetes Insulin, GLP-1 and SGLT2i? • Dandona P*, Petrie JR (co-PIs), Ghanim H, Boyle J, Lindsay R, Ford I. Triple therapy for T1DM with insulin, semaglutide and dapagliflozin. JDRF Strategic Research Award. $1.64M (2019-2022) • *State University of New York (SUNY)

  15. John Kerr Research Register Manager 01382 383 595 70 registrations from NHS GGC last week! www.nhsresearchscotland.org.uk/research-areas/diabetes

  16. Acknowledgements Thank you! @johnrpetrie @drjamesboyle @MetaMedTeam

More Related